» Articles » PMID: 34403752

Enhancing Therapeutic Performance of Personalized Cancer Vaccine Via Delivery Vectors

Overview
Specialty Pharmacology
Date 2021 Aug 17
PMID 34403752
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, personalized cancer vaccines have gained increasing attention as emerging immunotherapies with the capability to overcome interindividual differences and show great benefits for individual patients in the clinic due to the highly tailored vaccine formulations. A large number of materials have been studied as delivery vectors to enhance the therapeutic performance of personalized cancer vaccines, including artificial materials, engineered microorganisms, cells and cell derivatives. These delivery vectors with distinct features are employed to change antigen biodistributions and to facilitate antigen uptake, processing and presentation, improving the strength, velocity, and duration of the immune response when delivered by different strategies. Here, we provide an overview of personalized cancer vaccine delivery vectors, describing their materials, physicochemical properties, delivery strategies and challenges for clinical transformation.

Citing Articles

Immunotherapy Vaccines for Prostate Cancer Treatment.

He J, Wu J, Li Z, Zhao Z, Qiu L, Zhu X Cancer Med. 2024; 13(20):e70294.

PMID: 39463159 PMC: 11513549. DOI: 10.1002/cam4.70294.


DC-derived whole cell cytokine nano-regulator for remodelling extracellular matrix and synergizing tumor immunotherapy.

Lu J, Li Y, Gao X, Chen S, Jin Z, Guo X RSC Med Chem. 2024; .

PMID: 39345717 PMC: 11428036. DOI: 10.1039/d4md00496e.


Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine.

Yang C, Chen Y, Liu J, Zhang W, He Y, Chen F Adv Sci (Weinh). 2024; 11(30):e2400630.

PMID: 38867377 PMC: 11321648. DOI: 10.1002/advs.202400630.


Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis.

Amanzadeh Jajin E, Oraee Yazdani S, Zali A, Esmaeili A Oncol Rev. 2024; 18:1374513.

PMID: 38707486 PMC: 11066223. DOI: 10.3389/or.2024.1374513.


Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.

Huang X, Zhu X, Yang H, Li Q, Gai L, Sui X Molecules. 2024; 29(7).

PMID: 38611742 PMC: 11012694. DOI: 10.3390/molecules29071462.